Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations.

Human pathology - 1 May 2016

Harms Paul W, Hovelson Daniel H, Cani Andi K, Omata Kei, Haller Michaela J, Wang Michael L, Arps David, Patel Rajiv M, Fullen Douglas R, Wang Min, Siddiqui Javed, Andea Aleodor, Tomlins Scott A

Abstract excerpt

Porocarcinomas are a rare eccrine carcinoma with significant metastatic potential. Oncogenic drivers of porocarcinomas have been underexplored, with PIK3CA-activating mutation reported in 1 case. We analyzed 5 porocarcinomas by next-generation sequencing using the DNA component of the Oncomine Comprehensive Assay, which provides data on copy number changes and mutational events in 126 cancer-relevant genes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to DNA Mutational Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, erbB-1

Share to Genes, Tumor Suppressor

Share to High-Throughput Nucleotide Sequencing

Share to Immunohistochemistry

Share to Proto-Oncogene Proteins p21(ras)

Share to Young Adult

Source

Identifiers

PMID: 27067779
DOI: 10.1016/j.humpath.2015.12.015

Genes

HRAS
EGFR
ATM

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations.PMID 27067779Read ↗

Exploring the genetic driver events of eccrine poromas and porocarcinomas: a retrospective, cross-institutional study of 54 casesSemantic proximity Read ↗

Whole-exome sequencing in eccrine porocarcinoma indicates promising therapeutic strategies.Semantic proximity Read ↗

Whole-exome sequencing identifies distinct genomic aberrations in eccrine porocarcinomas and poromasSemantic proximity Read ↗

Comprehensive profiling of the mutational landscape of hidradenoma papilliferum validates key role of alterations in the PI3K/AKT pathway alterationsSemantic proximity Read ↗

High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma.Semantic proximity Read ↗

Molecular Profiling of Syringocystadenocarcinoma Papilliferum Reveals RAS-Activating Mutations.Semantic proximity Read ↗

Squamoid Eccrine Ductal Carcinoma Displays Ultraviolet Mutations and Intermediate Gene Expression Relative to Squamous Cell Carcinoma, Microcystic Adnexal Carcinoma, and Porocarcinoma.Semantic proximity Read ↗

Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinomaSemantic proximity Read ↗

Next-generation sequencing implicates oncogenic roles for p53 and JAK/STAT signaling in microcystic adnexal carcinomas.Semantic proximity Read ↗

Identification of potentially druggable molecular alterations in skin adnexal malignanciesSemantic proximity Read ↗

Molecular alterations in lesions of anogenital mammary-like glands and their mammary counterparts including hidradenoma papilliferum, intraductal papilloma, fibroadenoma and phyllodes tumor.Semantic proximity Read ↗

Sweat Gland Tumors Arising on Acral SitesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.